<DOC>
	<DOC>NCT02968004</DOC>
	<brief_summary>This will be an open-label, randomized, multicenter, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone deficiency.</brief_summary>
	<brief_title>Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1. Prepubertal children aged ≥3 years , and not yet 11 years for girls or not yet 12 years with either isolated GHD, or GH insufficiency as part of multiple pituitary hormone deficiency. 2. Confirmed diagnosis of GHD by two different GH provocation tests defined as a peak plasma GH level of ≤10 ng/mL, 3. Bone age (BA) is not older than chronological age and should be less than 10 for girls and less than 11 for boys. 4. Without prior exposure to any rhGH therapy (naïve patients). 5. Impaired height velocity defined as: o Annualized height velocity (HV) below the 25th percentile for CA (HV &lt; 0.7 SDS) and gender according 6. BMI must be within ±2 SDS of mean BMI for the chronological age and sex. 7. Baseline IGFI level of at least 1 SD below the mean IGFI level standardized for age and sex (IGFI SDS ≤1) 8. Normal calculated GFR 9. Normal 46XX karyotype for girls. 1. Children with prior history of leukemia, lymphoma, sarcoma or any other forms of cancer. 2. History of radiation therapy or chemotherapy 3. Malnourished children defined as BMI &lt; 2 SDS for age and sex 4. Children with psychosocial dwarfism 5. Children born small for gestational age (SGA birth weight and/or birth length &lt;2 SDS for gestational age) 6. Presence of antihGH antibodies at screening 7. Chromosomal abnormalities including Turner's syndrome, Laron syndrome, Noonan syndrome, PraderWilli syndrome, RussellSilver syndrome, SHOX mutations/deletions and skeletal dysplasias. 8. Concomitant administration of other treatments that may have an effect on growth 9. Major medical conditions and/or presence of contraindication to rhGH treatment. 10. Closed epiphyses 11. Known or suspected HIVpositive patient, or patient with advanced diseases such as AIDS or tuberculosis. 12. Drug, substance, or alcohol abuse. 13. Known hypersensitivity to the components of study medication. 14. Other causes of short stature such as celiac disease, uncontrolled primary hypothyroidism and rickets.</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>